Brief: Celcuity Announces FDA Approval Of Revtorpyk™ (Gedatolisib) For The Treatment Of Hr+/Her2-, Pik3ca Wild-Type Locally Advanced Or Metastatic Breast Cancer
14/07/2026 22:02
BRIEF-Celcuity Announces FDA Approval Of Revtorpyk™ (Gedatolisib) For The Treatment Of Hr+/Her2-, Pik3ca Wild-Type Locally Advanced Or Metastatic Breast Cancer July 14 (Reuters) - Celcuity Inc CELC.O:
CELCUITY ANNOUNCES FDA APPROVAL OF REVTORPYK™ (GEDATOLISIB) FOR THE TREATMENT OF HR+/HER2-, PIK3CA WILD-TYPE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
CELCUITY - ANTICIPATES REVTORPYK COMMERCIAL LAUNCH IN LATE Q3 2026
CELCUITY - TO SUBMIT SNDAS FOR REVTORPYK IN HR+/HER2-, PIK3CA MUTATED BREAST CANCER IN Q3 2026
Source text: ID:nGNXcYfpk
Further company coverage: CELC.O
((Reuters.Briefs@thomsonreuters.com;))